Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 20/20 | 1.00 |
| ▸ | FFAR4 | Q5NUL3 | 3/20 | 1.00 |
| ▸ | CHRM2 | P08172 | 1/20 | 1.00 |
| ▸ | S1PR1 | P21453 | 1/20 | 1.00 |
| ▸ | FPR1 | P21462 | 1/20 | 1.00 |
| ▸ | FPR3 | P25089 | 1/20 | 1.00 |
| ▸ | GPR183 | P32249 | 1/20 | 1.00 |
| ▸ | APLNR | P35414 | 1/20 | 1.00 |
| ▸ | GPR65 | Q8IYL9 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1551461 | 1.00 | FFAR1 (1.00) | FFAR1FFAR4CHRM2S1PR1FPR1 | |
| SCHEMBL19821417 | 0.92 | FFAR1 (0.84) | FFAR1FFAR4CHRM2S1PR1FPR1 | |
| SCHEMBL1550951 | 0.89 | FFAR1 (1.00) | FFAR1FFAR4CHRM2S1PR1FPR1 | |
| SCHEMBL14924233 | 0.88 | FFAR1 (0.79) | FFAR1FFAR4CHRM2S1PR1FPR1 | |
| SCHEMBL1551052 | 0.85 | FFAR1 (0.73) | FFAR1FFAR4CHRM2S1PR1FPR1 | |
| SCHEMBL1551253 | 0.84 | FFAR1 (1.00) | FFAR1FFAR4CHRM2S1PR1FPR1 | |
| SCHEMBL1550207 | 0.84 | FFAR1 (1.00) | FFAR1FFAR4CHRM2S1PR1FPR1 | |
| SCHEMBL1551391 | 0.84 | FFAR1 (1.00) | FFAR1FFAR4CHRM2S1PR1FPR1 | |
| SCHEMBL1550727 | 0.84 | FFAR1 (1.00) | FFAR1FFAR4CHRM2S1PR1FPR1 | |
| SCHEMBL1550924 | 0.83 | FFAR1 (1.00) | FFAR1FFAR4CHRM2S1PR1FPR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250171512-A1 | FGF21 VARIANTS | SANOFI SA (FR) | 2025-05-29 | — | — | US | disclosed |
| US-20250121034-A1 | STABILIZED PHARMACEUTICAL FORMULATIONS OF INSULIN ANALOGUES AND/OR INSULIN DERIVATIVES | SANOFI SA (FR) | 2025-04-17 | — | — | US | disclosed |
| US-20240366727-A1 | FGF21 COMPOUND / GLP-1R AGONIST COMBINATIONS WITH OPTIMIZED ACTIVITY RATIO | SANOFI SA (FR) | 2024-11-07 | — | — | US | disclosed |
| US-20240360194-A1 | New Peptides as Potent and Selective GIP Receptor Agonists | SANOFI (FR) | 2024-10-31 | — | — | US | disclosed |
| US-20240325499-A1 | FGF21 COMPOUND / GLP-1R AGONIST COMBINATIONS WITH OPTIMIZED ACTIVITY RATIO | SANOFI SA (FR) | 2024-10-03 | — | — | US | disclosed |
| US-20240316085-A1 | METHODS, AGENTS, AND DEVICES FOR LOCAL NEUROMODULATION OF AUTONOMIC NERVES | Tulavi Therapeutics, Inc. | 2024-09-26 | — | — | US | disclosed |
| EP-4399224-A1 | NEW PEPTIDES AS POTENT AND SELECTIVE GIP RECEPTOR AGONISTS | Sanofi (FR) | 2024-07-17 | — | — | EP | disclosed |
| US-12029733-B2 | Treatment of sepsis and related inflammatory conditions by local neuromodulation of the autonomic nervous system | Tulavi Therapeutics, Inc. (US) | 2024-07-09 | — | — | US | disclosed |
| CN-118159552-A | Novel peptides as potent and selective GIP receptor agonists | 赛诺菲 | 2024-06-07 | — | — | CN | disclosed |
| CN-109996557-B | Novel compounds as peptide GLP 1/glucagon/GIP receptor agonists | 赛诺菲 | 2024-05-03 | — | — | CN | disclosed |
| US-20220280497-A1 | TREATMENT OF SEPSIS AND RELATED INFLAMMATORY CONDITIONS BY LOCAL NEUROMODULATION OF THE AUTONOMIC NERVOUS SYSTEM | Tulavi Therapeutics, Inc. | 2022-09-08 | — | — | US | disclosed |
| CN-114939156-A | Stabilized pharmaceutical formulations of insulin aspart | 赛诺菲 | 2022-08-26 | — | — | CN | disclosed |
| US-20220227825-A1 | FGF21 VARIANTS | SANOFI SA (FR) | 2022-07-21 | — | — | US | disclosed |
| CN-105899190-B | Stabilized pharmaceutical formulations of insulin aspart | 赛诺菲 | 2022-06-14 | — | — | CN | disclosed |
| US-20220175710-A1 | COMBINATION THERAPY | AKERSHUS UNIVERSITETSSYKEHUS HF (NO) | 2022-06-09 | — | — | US | disclosed |
| CN-108026153-B | Novel exendin-4 derivatives as selective peptide dual GLP-1/glucagon receptor agonists | 赛诺菲 | 2022-05-27 | — | — | CN | disclosed |
| EP-3955906-A1 | COMBINATION THERAPY COMPRISING AN FFAR4 AGONIST AND AN ALPHA-7 NACHR AGONIST OR POSITIVE MODULATOR | Akershus Universitetssykehus HF (NO) | 2022-02-23 | — | — | EP | disclosed |
| US-11246879-B2 | Methods, agents, and devices for local neuromodulation of autonomic nerves | Tulai Therapeutics, Inc. (US) | 2022-02-15 | — | — | US | disclosed |
| US-20220040267-A1 | STABILIZED PHARMACEUTICAL FORMULATIONS OF INSULIN ANALOGUES AND/OR INSULIN DERIVATIVES | SANOFI SA (FR) | 2022-02-10 | — | — | US | disclosed |
| US-20220023392-A1 | STABILIZED PHARMACEUTICAL FORMULATIONS OF INSULIN ASPART | SANOFI SA (FR) | 2022-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240360194-A1 | New Peptides as Potent and Selective GIP Receptor Agonists | GIPR, GLP1R, GPR119 | FFAR1 134/4885FFAR4 111/4885CHRM2 2903/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.